Compared with obstructive sleep apnea, the incidence of central sleep apnea (CSA) is lower, but its causes are numerous, and the incidence varies greatly depending on the underlying factor. Clinically, the most common cause of CSA is heart failure. In 2025, the American Academy of Sleep Medicine published a clinical practice guideline for the treatment of CSA in adults, which provides important updates to previous recommendations, especially regarding the treatment of heart failure-related CSA. The updates cover various treatment options, including continuous positive airway pressure, adaptive servo-ventilation, low-flow oxygen therapy, acetazolamide, and transvenous phrenic nerve stimulation. The new guideline emphasizes that treatment should be individualized based on the etiology, clinical characteristics, coexisting diseases, and polysomnography findings of each patient. It also highlights the importance of outcome measures such as quality of life, patient-reported outcomes, and hypoxic burden. This article interprets the main recommendations of the guideline, introduces some important research background, and raises several considerations based on clinical practice.